Amalgamated Bank Raises Stock Position in Insulet Co. (NASDAQ:PODD)

Amalgamated Bank increased its holdings in shares of Insulet Co. (NASDAQ:PODDFree Report) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,818 shares of the medical instruments supplier’s stock after purchasing an additional 634 shares during the quarter. Amalgamated Bank’s holdings in Insulet were worth $3,001,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PODD. Allworth Financial LP boosted its stake in Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 92 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at about $31,000. First Manhattan Co. purchased a new position in Insulet during the 4th quarter worth approximately $35,000. Massmutual Trust Co. FSB ADV increased its position in Insulet by 228.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 263 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 183 shares during the period. Finally, HM Payson & Co. purchased a new stake in Insulet in the third quarter valued at approximately $48,000.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 20,000 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $164.33, for a total value of $3,286,600.00. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at $421,835.11. The sale was disclosed in a filing with the SEC, which is available at this link. 0.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on PODD. Piper Sandler lowered their target price on shares of Insulet from $325.00 to $250.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. SVB Leerink began coverage on shares of Insulet in a report on Monday, October 16th. They issued an “outperform” rating and a $184.00 target price for the company. Stifel Nicolaus increased their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Morgan Stanley upgraded Insulet from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $185.00 to $234.00 in a research report on Monday, December 4th. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Insulet in a research report on Monday, October 16th. Four investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average target price of $250.40.

View Our Latest Research Report on Insulet

Insulet Price Performance

Insulet stock opened at $192.55 on Friday. The company has a debt-to-equity ratio of 2.26, a quick ratio of 2.35 and a current ratio of 3.26. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The company has a market cap of $13.45 billion, a P/E ratio of 112.60, a price-to-earnings-growth ratio of 2.13 and a beta of 1.05. The business has a fifty day moving average of $202.87 and a two-hundred day moving average of $188.65.

About Insulet

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

Further Reading

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.